Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanhe Li

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|September 13, 2023
Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and MetastasisWenjuan Li, Shanhe Li, Gang Xu, et al.
Molecular Pharmaceutics|February 26, 2020
Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor MicroenvironmentZhenlei Zhang, Juzheng Zhang, Ming Jiang, et al.
Journal of Medicinal Chemistry|March 24, 2026
Developing a Multitargeted Anticancer Bi-Copper(II)-Centered Thiocarbohydrazone Agent Based on Lys-199 and His-242 Residues in the IIA Subdomain of Human Serum AlbuminShanhe Li, Xiaojun Wang, Ming Jiang, et al.
Journal of Medicinal Chemistry|April 16, 2021
Dithiocarbazate-Copper Complexes for Bioimaging and Treatment of Pancreatic CancerYi Gou, MeiRong Chen, Shanhe Li, et al.
Journal of Medicinal Chemistry|May 23, 2023
Developing a Gadolinium(III) Compound Based on Apoferritin for Targeted Magnetic Resonance Imaging and Dual-Modal Therapy of CancerXueyu Man, Tongfu Yang, Wenjuan Li, et al.
Journal of Medicinal Chemistry|November 13, 2020
Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and ApoptosisJuzheng Zhang, Zhenlei Zhang, Ming Jiang, et al.
Journal of Medicinal Chemistry|March 29, 2024
Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor MicroenvironmentXueyu Man, Shanhe Li, Gang Xu, et al.
Journal of Medicinal Chemistry|September 19, 2024
Developing a Rhodium(III) Complex to Reprogram the Tumor Immune and Metabolic Microenvironments: Overcoming Multidrug Resistance and Metastasis in Non-Small Cell Lung CancerWenjuan Li, Shanhe Li, Minghui Zhu, et al.
Angewandte Chemie (International Ed. in English)|September 19, 2024
Anticancer Tetranuclear Cu(I) Complex Catalyzes a Click Reaction to Synthesize a Chemotherapeutic Agent in situ to Achieve Targeted Dual-Agent Combination Therapy for CancerXueyu Man, Wenjuan Li, Minghui Zhu, et al.
Journal of Medicinal Chemistry|March 24, 2022
Developing a Novel Indium(III) Agent Based on Human Serum Albumin Nanoparticles: Integrating Bioimaging and TherapyZhenlei Zhang, Tongfu Yang, Juzheng Zhang, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|September 13, 2023
Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and MetastasisWenjuan Li, Shanhe Li, Gang Xu, et al.
Molecular Pharmaceutics|February 26, 2020
Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor MicroenvironmentZhenlei Zhang, Juzheng Zhang, Ming Jiang, et al.
Journal of Medicinal Chemistry|March 24, 2026
Developing a Multitargeted Anticancer Bi-Copper(II)-Centered Thiocarbohydrazone Agent Based on Lys-199 and His-242 Residues in the IIA Subdomain of Human Serum AlbuminShanhe Li, Xiaojun Wang, Ming Jiang, et al.
Journal of Medicinal Chemistry|April 16, 2021
Dithiocarbazate-Copper Complexes for Bioimaging and Treatment of Pancreatic CancerYi Gou, MeiRong Chen, Shanhe Li, et al.
Journal of Medicinal Chemistry|May 23, 2023
Developing a Gadolinium(III) Compound Based on Apoferritin for Targeted Magnetic Resonance Imaging and Dual-Modal Therapy of CancerXueyu Man, Tongfu Yang, Wenjuan Li, et al.
Journal of Medicinal Chemistry|November 13, 2020
Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and ApoptosisJuzheng Zhang, Zhenlei Zhang, Ming Jiang, et al.
Journal of Medicinal Chemistry|March 29, 2024
Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor MicroenvironmentXueyu Man, Shanhe Li, Gang Xu, et al.
Journal of Medicinal Chemistry|September 19, 2024
Developing a Rhodium(III) Complex to Reprogram the Tumor Immune and Metabolic Microenvironments: Overcoming Multidrug Resistance and Metastasis in Non-Small Cell Lung CancerWenjuan Li, Shanhe Li, Minghui Zhu, et al.
Angewandte Chemie (International Ed. in English)|September 19, 2024
Anticancer Tetranuclear Cu(I) Complex Catalyzes a Click Reaction to Synthesize a Chemotherapeutic Agent in situ to Achieve Targeted Dual-Agent Combination Therapy for CancerXueyu Man, Wenjuan Li, Minghui Zhu, et al.
Journal of Medicinal Chemistry|March 24, 2022
Developing a Novel Indium(III) Agent Based on Human Serum Albumin Nanoparticles: Integrating Bioimaging and TherapyZhenlei Zhang, Tongfu Yang, Juzheng Zhang, et al.
Pageof 3